Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) has announced the addition of Ron Philip, President and CEO of Orbital ...

Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The company had revenue of $201.30 million during the quarter, compared to analyst estimates of $201.25 million.

Highlights,A prominent asset manager increases its stake in a biotech company.,Institutional adjustments spotlight changes in ...

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $58.31, a high ...

NEW YORK, NY / ACCESS Newswire / April 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

KLP Kapitalforvaltning AS purchased a new stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Free Report) in the 4th ...

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the presentation of updated data from its Open-Label Extension (OLE) study (ZYN2-CL-017) evaluating the safety and effectiveness of ...

The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...

In the latest quarter, 13 analysts provided ratings for Harmony Biosciences Hldgs (NASDAQ:HRMY), showcasing a mix of bullish and bearish perspectives. The following table encapsulates their recent ...

Data to be Presented at the Hot Topics in Child Neurology Podium Presentation Session at the American Academy of Neurology Annual Meeting Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY ...